Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“however, just like for ACE inhibitors, there is currently insufficient scientific evidence to judge whether use of DPP4 inhibitors impacts adversely on type 2 diabetes patients with COVID-19 (28).”
From ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency (2020) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultHamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676 · cited 9×
“1), and generates vasodilatory Ang (1-7), collectively modulating often opposing actions of Ang II and ACE through Ang and angiotensin (1-7) receptors.”
BackgroundInfluentialGrasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 2×
“form ACE2(1-740), however the biological importance of sACE2 remains uncertain.”
BackgroundCase-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis
Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00547-2020 · Cited by 3,680
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“Consistent with these findings, results of large trials examining the safety of saxagliptin, alogliptin, sitagliptin, and linagliptin in humans with T2D at risk for cardiovascular or renal disease did not reveal clinically relevant safety concerns related to infections, immune or inflammatory disorders (96-100).”
BackgroundResult
Research works printed but not linked: 1
- Audit I. ICNARC Report on COVID-19 in Critical Care. In. April 10 2020 ed: London, UK: Intensive Care National Audit & Research Centre (ICNARC); 2020. https:// www.icnarc.org/About/Latest-News/2020/04/04/ Report-On-2249-Patients-Critically-Ill-With-Covid-19
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al-Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05180-x · Cited by 813
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N., Singla, V., Khare, S., & Srivastava, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.044 · Cited by 776
Obesity ‑ a risk factor for increased COVID‑19 prevalence, severity and lethality (Review)
Petrakis, D., Margină, D., Tsarouhas, K., Tekos, F., Stan, M., Nikitovic, D., Kouretas, D., Spandidos, D., & Tsatsakis, A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11127 · Cited by 388
Diabetes, infection risk and COVID-19
Erener, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101044 · Cited by 351
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Drucker, D. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.016 · Cited by 272
“Readers are referred to earlier reviews that predominantly address clinical and therapeutic guidance (Bornstein et al., 2020; Drucker, 2020; Lim et al., 2021).”
InfluentialSelf-citationPathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression
Bohn, M. K., Hall, A., Sepiashvili, L., Jung, B., Steele, S., & Adeli, K. (2020) · Physiology · doi:10.1152/physiol.00019.2020 · Cited by 258
COVID-19 and metabolic disease: mechanisms and clinical management
Steenblock, C., Schwarz, P. E. H., Ludwig, B., Linkermann, A., Zimmet, P., Kulebyakin, K., Tkachuk, V. A., Markov, A. G., Lehnert, H., de Angelis, M. H., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00244-8 · Cited by 246
Solerte, S. B., D’Addio, F., Trevisan, R., Lovati, E., Rossi, A., Pastore, I., Dell’Acqua, M., Ippolito, E., Scaranna, C., Bellante, R., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1521 · Cited by 244
Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC)
Sherif, Z. A., Gomez, C. R., Connors, T. J., Henrich, T. J., Reeves, W. B., & RECOVER Mechanistic Pathway Task Force (2023) · eLife · doi:10.7554/elife.86002 · Cited by 237
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Landstra, C. P., & de Koning, E. J. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649525 · Cited by 206
Khunti, K., Knighton, P., Zaccardi, F., Bakhai, C., Barron, E., Holman, N., Kar, P., Meace, C., Sattar, N., Sharp, S., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00050-4 · Cited by 192
Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking
Engin, A. B., Engin, E. D., & Engin, A. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103411 · Cited by 187
Viral infiltration of pancreatic islets in patients with COVID-19
Steenblock, C., Richter, S., Berger, I., Barovic, M., Schmid, J., Schubert, U., Jarzebska, N., von Mässenhausen, A., Linkermann, A., Schürmann, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23886-3 · Cited by 181
Coate, K. C., Cha, J., Shrestha, S., Wang, W., Gonçalves, L. M., Almaça, J., Kapp, M. E., Fasolino, M., Morgan, A., Dai, C., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.006 · Cited by 177
Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup
Xu, H., Sheng, S., Luo, W., Xu, X.-F., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277161 · Cited by 174
Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19
Mauvais-Jarvis, F. (2020) · Diabetes · doi:10.2337/dbi19-0023 · Cited by 168
The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis
Chen, J., Wu, C., Wang, X., Yu, J., & Sun, Z. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.574541 · Cited by 164
Interactions of SARS-CoV-2 with the Blood–Brain Barrier
Erickson, M. A., Rhea, E. M., Knopp, R. C., & Banks, W. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052681 · Cited by 165
Dowey, R., Iqbal, A., Heller, S. R., Sabroe, I., & Prince, L. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678771 · Cited by 164
Scheen, A. J., Marre, M., & Thivolet, C. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.008 · Cited by 159
Flavonoids against the SARS-CoV-2 induced inflammatory storm
Líšková, A., Samec, M., Koklesová, L., Samuel, S. M., Zhai, K., AL-Ishaq, R. K., Abotaleb, M., Nosáľ, V., Kajo, K., Ashrafizadeh, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111430 · Cited by 155
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes
Bigdelou, B., Sepand, M. R., Najafikhoshnoo, S., Negrete, J. A. T., Sharaf, M., Ho, J. Q., Sullivan, I., Chauhan, P. S., Etter, M. M., Shekarian, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890517 · Cited by 143
COVID-19 and Diabetes: A Collision and Collusion of Two Diseases
Feldman, E. L., Savelieff, M. G., Hayek, S. S., Pennathur, S., Kretzler, M., & Pop-Busui, R. (2020) · Diabetes · doi:10.2337/dbi20-0032 · Cited by 136
Kyrou, I., Karteris, E., Robbins, T., Chatha, K. K., Drenos, F., & Randeva, H. S. (2020) · BMC Medicine · doi:10.1186/s12916-020-01697-5 · Cited by 135
The impact of COVID-19 on people with diabetes in Brazil
Barone, M. T. U., Harnik, S. B., de Luca, P. V., Lima, B. L. D. S., Pineda-Wieselberg, R. J., Ngongo, B., Pedrosa, H. C., Netto, A. P., Franco, D. R., de Souza, M. D. F. M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108304 · Cited by 135
Insulin resistance in COVID-19 and diabetes
Govender, N., Khaliq, O. P., Moodley, J., & Naicker, T. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.004 · Cited by 135
COVID-19 in people living with diabetes: An international consensus
Caballero, A. E., Ceriello, A., Misra, A., Aschner, P., McDonnell, M. E., Hassanein, M., Ji, L., Mbanya, J. C., & Fonseca, V. A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107671 · Cited by 132
Impact of Diabetes in Patients Diagnosed With COVID-19
Abu‐Farha, M., Al‐Mulla, F., Thanaraj, T. A., Kavalakatt, S., Ali, H., Ghani, M. A., & Abubaker, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576818 · Cited by 131
Dietary Regulation of Immunity
Lee, A. H., & Dixit, V. D. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.013 · Cited by 123
COVID-19 in diabetic patients: Related risks and specifics of management
Orioli, L., Hermans, M. P., Thissen, J.-P., Maiter, D. M., Vandeleene, B., & Yombi, J. C. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.05.001 · Cited by 130
Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course
Bansal, R., Gubbi, S., & Muniyappa, R. (2020) · Endocrinology · doi:10.1210/endocr/bqaa112 · Cited by 113
Singh, A. K., & Khunti, K. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-011857 · Cited by 122
Diabetes and COVID-19: The past, the present, and the future
Pranata, R., Henrina, J., Raffaello, W. M., Lawrensia, S., & Huang, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154814 · Cited by 121
Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review
Caramaschi, S., Kapp, M., Miller, S., Eisenberg, R., Johnson, J. E., Epperly, G., Maiorana, A., Silvestri, G., & Giannico, G. A. (2021) · Modern Pathology · doi:10.1038/s41379-021-00814-w · Cited by 118
ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
Saponaro, F., Rutigliano, G., Sestito, S., Bandini, L., Storti, B., Bizzarri, R., & Zucchi, R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.588618 · Cited by 116
Perez-Belmonte, L. M., Torres-Peña, J. D., Lopez-Carmona, M. D., Ayala-Gutiérrez, M. M., Fuentes, F. J., Huerta, L. D. J., Muñoz, J. A., Rubio‐Rivas, M., Madrazo, M., García, M. G., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01832-2 · Cited by 110
Kruglikov, I. L., Shah, M., & Scherer, P. E. (2020) · eLife · doi:10.7554/elife.61330 · Cited by 110
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0361 · Cited by 107
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Valencia, I., Peiró, C., Lorenzo, Ó., Sánchez-Ferrer, C. F., Eckel, J., & Romacho, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01161 · Cited by 99
Covid-19 and Diabetes: A Complex Bidirectional Relationship
Muniangi-Muhitu, H., Akalestou, E., Salem, V., Misra, S., Oliver, N. S., & Rutter, G. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.582936 · Cited by 104
Association of COVID-19 with Comorbidities: An Update
Chatterjee, S., Nalla, L. V., Sharma, M., Sharma, N., Singh, A. A., Malim, F. M., Ghatage, M., Mukarram, M., Pawar, A., Parihar, N., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00181 · Cited by 104
Fadini, G. P., Morieri, M. L., Longato, E., Bonora, B. M., Pinelli, S., Selmin, E., Voltan, G., Falaguasta, D., Tresso, S., Costantini, G., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14097 · Cited by 103
Association of vitamin D status with COVID-19 and its severity
Bae, J. H., Choe, H. J., Holick, M. F., & Lim, S. K. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09705-6 · Cited by 102
Singh, A. K., & Khunti, K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108266 · Cited by 101
Type 2 diabetes mellitus and COVID-19: a narrative review
Corrao, S., Pinelli, K., Vacca, M., Raspanti, M., & Argano, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609470 · Cited by 97
“org 5 concomitant sepsis or severe impairment of hepatic and renal function (72).”
BackgroundIs diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)?
Pugliese, G., Vitale, M., Resi, V., & Orsi, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01586-6 · Cited by 97
Diabetes and COVID-19; A Bidirectional Interplay
Kazakou, P., Lambadiari, V., Ikonomidis, I., Kountouri, A., Panagopoulos, G. N., Athanasopoulos, S., Korompoki, E., Kalomenidis, I., Dimopoulos, M. A., & Mitrakou, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.780663 · Cited by 96
Characteristics and outcomes of COVID ‐19 in hospitalized patients with and without diabetes
Al‐Salameh, A., Lanoix, J., Bennis, Y., Andréjak, C., Brochot, É., Deschasse, G., Dupont, H., Goëb, V., Jaureguy, M., Lion, S., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3388 · Cited by 95
A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic
Korytkowski, M., Antinori-Lent, K., Drincic, A., Hirsch, I. B., McDonnell, M. E., Rushakoff, R., & Muniyappa, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa342 · Cited by 89
Bidirectional causal associations between type 2 diabetes and COVID‐19
Cao, H., Baranova, A. V., Wei, X., Wang, C., & Zhang, F. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28100 · Cited by 94
SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease
Menon, R., Otto, E. A., Sealfon, R. S. G., Nair, V., Wong, A. K., Theesfeld, C. L., Chen, X., Wang, Y., Boppana, A., Luo, J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.015 · Cited by 92
Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Qusty, N. F., & Alexiou, A. T. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210902115650 · Cited by 91
Diabetes and COVID-19: Global and regional perspectives
Jeong, I., Yoon, K., & Lee, M. K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108303 · Cited by 91
The Impact of SARS-Cov-2 Virus Infection on the Endocrine System
Somasundaram, N. P., Ranathunga, I., Ratnasamy, V., Wijewickrama, P. S. A., Dissanayake, H. A., Yogendranathan, N., Gamage, K. K. K., de Silva, N. L., Sumanatilleke, M., Katulanda, P., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa082 · Cited by 94
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Baggio, L. L., Varin, E. M., Koehler, J. A., Cao, X., Lokhnygina, Y. V., Stevens, S. R., Holman, R. R., & Drucker, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17556-z · Cited by 88
Self-citationDiabetes, obesity and COVID ‐19: A complex interplay
Vas, P. R. J., Hopkins, D., Feher, M. D., Rubino, F., & Whyte, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14134 · Cited by 85
Gudé, F., Fernández‐Merino, C., Ferreiro, L., Lado‐Baleato, Ó., Espasandín-Domínguez, J., Hervada, X., Cadarso-Suárez, C., & Valdés, L. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa209 · Cited by 84
Nguyen, N. N., Ho, D. S., Nguyen, H. S., Ho, D. K. N., Li, H., Lin, C.-Y., Chiu, H., & Chen, Y. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155196 · Cited by 84
Behavioral Food Addiction During Lockdown: Time for Awareness, Time to Prepare the Aftermath
Chérikh, F., Frey, S., Bel, C., Attanasi, G., Alifano, M., & Iannelli, A. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04649-3 · Cited by 82
Lally, M., Tsoukas, P., Halladay, C. W., O’Neill, E., Gravenstein, S., & Rudolph, J. L. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.10.031 · Cited by 79
Levy, E. H., DELVIN, E. E., Marcil, V., & Spahis, S. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00298.2020 · Cited by 79
Dalamaga, Μ., Christodoulatos, G. S., Karampela, Ι., Vallianou, N. G., & Apovian, C. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00436-y · Cited by 78
Barrera, F. J., Shekhar, S., Wurth, R., Moreno-Peña, P. J., Ponce, O. J., Hajdenberg, M., Álvarez‐Villalobos, N. A., Hall, J. E., Schiffrin, E. L., Eisenhofer, G., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa102 · Cited by 75
The Australian response to the COVID-19 pandemic and diabetes – Lessons learned
Andrikopoulos, S., & Johnson, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108246 · Cited by 73
Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic
South, K., McCulloch, L. J., McColl, B. W., Elkind, M. S. V., Allan, S. M., & Smith, C. J. (2020) · International Journal of Stroke · doi:10.1177/1747493020943815 · Cited by 73
Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms
Li, G., Chen, Z., Lv, Z., Li, H., Chang, D., & Lu, J. (2021) · International Journal of Endocrinology · doi:10.1155/2021/7394378 · Cited by 71
Chen, M., Zhu, B., Chen, D., Hu, X., Xu, X., Shen, W., Hu, C., Li, J., & Qu, S. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.004 · Cited by 71
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 70
Gene signatures of SARS-CoV/SARS-CoV-2-infected ferret lungs in short- and long-term models
Liu, H.-L., Yeh, I., Phan, N. N., Wu, Y., Yen, M., Hung, J., Chiao, C.-C., Chen, C., Sun, Z., Jiang, J., et al. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104438 · Cited by 68
Rhee, S. Y., Lee, J.-W., Nam, H., Kyoung, D., Shin, D. W., & Kim, D. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0206 · Cited by 67
Kahkoska, A. R., Abrahamsen, T. J., Alexander, G. C., Bennett, T. D., Chute, C. G., Haendel, M. A., Klein, K. R., Mehta, H. B., Miller, J. D., Moffitt, R. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0065 · Cited by 67
Manejo de la diabetes mellitus en tiempos de COVID-19
Paz‐Ibarra, J. (2020) · ACTA MEDICA PERUANA · doi:10.35663/amp.2020.372.962 · Cited by 66
Infante, M., Buoso, A., Pieri, M., Lupisella, S., Nuccetelli, M., Bernardini, S., Fabbri, A., Iannetta, M., Andreoni, M., Colizzi, V., et al. (2021) · Journal of the American Nutrition Association · doi:10.1080/07315724.2021.1877580 · Cited by 65
Clinical characteristics of 1007 intensive care unitpatients with SARS-CoV-2 pneumonia
Glybochko, P. V., Fomin, V. V., Avdeev, S. N., Moiseev, S. V., Yavorovskiy, A. G., Brovko, M., Umbetova, K., Алиев, В. А., Львовна, Б. Е., Bondarenko, I., et al. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-2-21-29 · Cited by 65
Albogami, Y., Cusi, K. J., Daniels, M. J., Wei, Y. J., & Winterstein, A. G. (2021) · Diabetes Care · doi:10.2337/dc20-1794 · Cited by 63
Hariyanto, T. I., Intan, D., Hananto, J. E., Putri, C., & Kurniawan, A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109031 · Cited by 60
The Stress Axis in Obesity and Diabetes Mellitus: An Update
Gianotti, L., Belcastro, S., D’Agnano, S., & Tassone, F. (2021) · Endocrines · doi:10.3390/endocrines2030031 · Cited by 59
Spike in Diabetic Ketoacidosis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic
Chao, L. C., Vidmar, A. P., & Georgia, S. K. (2021) · Diabetes Care · doi:10.2337/dc20-2733 · Cited by 59
Helminth coinfection and COVID-19: An alternate hypothesis
Hays, R., Pierce, D. R., Giacomin, P., Loukas, A. C., Bourke, P., & McDermott, R. A. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008628 · Cited by 58
Tang, B., Yan, C., Shen, X., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885029 · Cited by 56
Glybochko, P. V., Fomin, V. V., Moiseev, S. V., Avdeev, S. N., Yavorovskiy, A. G., Brovko, M., Umbetova, K., Алиев, В. А., Львовна, Б. Е., Bondarenko, I., et al. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-3-25-36 · Cited by 55
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
Senger, M. R., Evangelista, T. C. S., Dantas, R. F., Santana, M. V., Gonçalves, L. C. S., Neto, L. R. D. S., Ferreira, S. B., & Silva, F. P. (2020) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200254 · Cited by 55
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Mechanisms of COVID-19 pathogenesis in diabetes
Narasimhulu, C. A., & Singla, D. K. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00204.2022 · Cited by 53
The dark side of the spoon - glucose, ketones and COVID-19: a possible role for ketogenic diet?
Paoli, A., Gorini, S., & Caprio, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02600-9 · Cited by 53
Metabolic risk factors and risk of Covid-19: A systematic review and meta-analysis
Moazzami, B., Chaichian, S., Kasaeian, A., Djalalinia, S., Akhlaghdoust, M., Eslami, M., & Broumand, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243600 · Cited by 50
Perakakis, N., Harb, H., Hale, B. G., Varga, Z., Steenblock, C., Kanczkowski, W., Alexaki, V. I., Ludwig, B., Mirtschink, P., Solimena, M., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00154-7 · Cited by 51
SARS‐CoV‐2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors
Stilhano, R. S., Costa, A. J., Nishino, M. S., Shams, S., Bartolomeo, C. S., Breithaupt‐Faloppa, A. C., Silva, E. A., López, A., Prado, C. M., & Ureshino, R. P. (2020) · The FASEB Journal · doi:10.1096/fj.202001394rr · Cited by 49
Coronavirus disease 2019 (COVID‐19) update: From metabolic reprogramming to immunometabolism
Rudiansyah, M., Jasim, S. A., pour, Z. G. M., Athar, S. S., Jeda, A. S., Doewes, R. I., Jalil, A. T., Bokov, D. O., Mustafa, Y. F., Noroozbeygi, M., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27929 · Cited by 49
Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910256 · Cited by 43
COVID-19: Impact of and on Diabetes
Schofield, J. D., Leelarathna, L., & Thabit, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00847-5 · Cited by 48
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.005 · Cited by 48
Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic
Pasquel, F. J., & Umpierrez, G. E. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820923045 · Cited by 44
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Galimberti, S., Baldini, C., Baratè, C., Ricci, F., Balducci, S., Grassi, S., Ferro, F., Buda, G., Benedetti, E., Fazzi, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104866 · Cited by 47
COVID-19 and Cardiovascular Comorbidities
Müller‐Wieland, D., Marx, N., Dreher, M., Fritzen, K., & Schnell, O. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1269-1405 · Cited by 47
COVID-19: Diabetes Perspective—Pathophysiology and Management
Dallavalasa, S., Tulimilli, S. V., Janhavi, P., Ramachandra, R., Madhunapantula, S. V., & Veeranna, R. P. (2023) · Pathogens · doi:10.3390/pathogens12020184 · Cited by 47
Bouhanick, B., Cracowski, J., & Faillie, J.-L. (2020) · Therapies · doi:10.1016/j.therap.2020.05.006 · Cited by 47
Endocrine Conditions and COVID-19
Shekhar, S., Wurth, R., Kamilaris, C. D. C., Eisenhofer, G., Barrera, F. J., Hajdenberg, M., Tonleu, J. T., Hall, J. E., Schiffrin, E. L., Porter, F. D., et al. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1172-1352 · Cited by 48
Endocrine disrupting chemicals and COVID-19 relationships: A computational systems biology approach
Wu, Q., Coumoul, X., Grandjean, P., Barouki, R., & Audouze, K. (2020) · Environment International · doi:10.1016/j.envint.2020.106232 · Cited by 48
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J
- ORCID
- Drucker, Daniel J
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-04-15
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7184382
- OpenAlex
- W3015989800
- Cited by
- 399
- References
- 132
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 13 · 2023: 37 · 2022: 72 · 2021: 100 · 2020: 162
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF19SA0035502)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- type 2 diabetes, COVID-19 pandemic, SARS-CoV-2, ACE2, dipeptidyl peptidase IV, DPP-4 inhibitors, glucose-lowering agents, immunomodulation, glucose homeostasis, inflammation
- MeSH terms
- Betacoronavirus, Receptors, Coronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin, Peptidyl-Dipeptidase A, Lung, Obesity, Pneumonia, Viral, Receptors, Virus, Risk Factors, Serine Endopeptidases, Coronavirus Infections, Dipeptidyl Peptidase 4, Gastrointestinal Tract, Dipeptidyl-Peptidase IV Inhibitors, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.